KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueEBIATGross ProfitLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetReceivables - OtherShares IssuedShares OutstandingShares Outstanding
Ratios

Supernus Pharmaceuticals (SUPN) Other Gross PP&E Adjustments (2016 - 2026)

Supernus Pharmaceuticals has reported Other Gross PP&E Adjustments over the past 15 years, most recently at -$14.6 million for Q4 2025.

  • Quarterly Other Gross PP&E Adjustments fell 139.21% to -$14.6 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$14.6 million through Dec 2025, down 139.21% year-over-year, with the annual reading at -$14.6 million for FY2025, 139.21% down from the prior year.
  • Other Gross PP&E Adjustments was -$14.6 million for Q4 2025 at Supernus Pharmaceuticals, down from -$13.5 million in the prior quarter.
  • Over five years, Other Gross PP&E Adjustments peaked at $28.0 million in Q1 2021 and troughed at -$36.4 million in Q2 2022.
  • The 5-year median for Other Gross PP&E Adjustments is -$8.9 million (2021), against an average of -$4.0 million.
  • The largest YoY upside for Other Gross PP&E Adjustments was 202.33% in 2021 against a maximum downside of 251.54% in 2021.
  • A 5-year view of Other Gross PP&E Adjustments shows it stood at -$28.7 million in 2021, then soared by 39.11% to -$17.5 million in 2022, then skyrocketed by 32.87% to -$11.7 million in 2023, then surged by 48.01% to -$6.1 million in 2024, then plummeted by 139.21% to -$14.6 million in 2025.
  • Per Business Quant, the three most recent readings for SUPN's Other Gross PP&E Adjustments are -$14.6 million (Q4 2025), -$13.5 million (Q3 2025), and -$7.8 million (Q2 2025).